Evidence map›Paper›PMID 40495217›Full record

ReviewCell & bioscience2025

Alpha fetoprotein (AFP)-producing gastric cancer: clinicopathological features and treatment strategies.

Bixian Luo, Zelai Wu, Chengyu Hu, Weixun Xie, Jun He, Hongming Liu, Dong Cao, Yong Liu, Yuxin Zhong, Weihua Gong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. [Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bixian Luo *Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Zelai Wu *Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Chengyu Hu *Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Weixun XieDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Jun HeDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Hongming LiuDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Dong CaoDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Yong LiuDepartment of Gastric Surgery, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China. libraly@126.com.
Yuxin ZhongDepartment of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zhongyuxin@cicams.ac.cn.
Weihua GongDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, People's Republic of China. weihuagong@zju.edu.cn.ORCID http://orcid.org/0000-0002-0213-7313

Funding

Key Research and Development Program of Zhejiang Province 2025C02054National Natural Science Foundation of China 82470416NIEHS NIH HHS 27304C2054
6 · The paper itself

Abstract

Alpha-fetoprotein (AFP) is a widely recognized tumor marker for hepatocellular carcinoma and yolk sac tumors. Alpha-fetoprotein-producing gastric cancer (AFPGC) is a rare but highly malignant subtype of gastric cancer associated with poor prognosis. It is characterized by AFP positivity detected in serum or immunohistochemical staining, may along with hepatocellular differentiation. In recent years, advancements in molecular biology and therapeutic agents have led to a deeper understanding of AFPGC. However, the mechanisms underlying its tumorigenesis and invasive metastasis remain unclear. This article summarizes the traits of AFP, its clinicopathological features, and therapeutic strategies for AFP-positive gastric cancer, providing a better understanding and reference for the clinical diagnosis and treatment of AFPGC.

Indexed as

Alpha fetoproteinClinical and histopathological featuresGastric cancerTreatment strategies

Identifiers

PMID40495217
PMCPMC12153134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.